Medicines Co: Company Report
The Medicines Company is a global pharmaceutical company focused on advancing the treatment of critical care patients through the delivery of medicines to the worldwide hospital marketplace. The Company has two marketed products, Angiomax (bivalirudin) and Cleviprex (clevidipine butyrate) injectable emulsion, two products in late-stage development, cangrelor and oritavancin, which the Company acquired in February 2009, and one compound, CU-2010, scheduled to enter clinical development during 2009.
| Stock Activity |
|---|
|
Last Price |
7.66 |
|
52 Week High |
14.51 |
|
52 Week Low |
6.15 |
|
Volume |
489,127 |
|
Average Daily Volume (13wk) |
337,480 |
|
50 Day Moving Average |
8.23 |
|
200 Day Moving Average |
8.57 |
|
Volatility (beta) |
0.76 |
| Stock Price History |
|---|
| | Change | Relative Strength |
|---|
| fyi |
Last 3 Months |
-3.4% |
45 |
|
Last 6 Months |
-8.1% |
33 |
| fyi |
Last 12 Months |
-47.6% |
9 |
Historical charts
| Institutional Statistics |
|---|
| Analyst Consensus | Hold | | Institutional Ownership | 102.10% |
More Analyst Ratings
Want to learn how to evaluate a stock? Walk through the steps using the Research Wizard. | advertisement
| Financials |
|---|
| | Last 12 Months | 5 Year Growth |
|---|
|
Sales |
396.1 Mil |
32.4% |
|
Income |
-6.9 Mil |
NA |
|
Dividend Rate |
0.00 |
NA |
|
Dividend Yield |
0.00% |
0.00% |
More financials
| Fundamental Data |
|---|
| Debt/Equity Ratio | NA | | Gross Margin | 71.67% | | Net Profit Margin | -1.75% | | Total Shares Outstanding | 52.9 Mil | | Market Capitalization | 404.99 Mil | | Earnings/Share | -0.13 |
More financial ratios
| Earnings Estimates
|
|---|
| Qtr(12/09) EPS Estimate |
-0.15 |
| FY(12/09) EPS Estimate |
-0.20 |
| Current P/E |
NA |
| FY(12/10) EPS Estimate |
0.29 |
| Forward P/E |
26.41 |
| Next Earnings Release:
N/A | | More analyst estimates
|
Recent News